|Day Low/High||4.10 / 4.55|
|52 Wk Low/High||3.42 / 8.11|
Board Accepts Resignations of Directors Peter J. Crowley and Michael D.
Provides Additional Medicare Reimbursement up to 65% of the Cost of AZEDRA Prescribed for Inpatient Medicare Patients
In trading on Monday, shares of Progenics Pharmaceuticals, Inc. crossed below their 200 day moving average of $4.83, changing hands as low as $4.72 per share.
Top-line Data Now Expected by Year End Reaches Alignment with FDA on Regulatory Path; Company to Submit NDA Following Positive CONDOR Data Completed Enrollment in Pivotal Phase 3 Trial in Eight Months NEW YORK, Aug.
NEW YORK, Aug. 01, 2019 (GLOBE NEWSWIRE) -- Progenics Pharmaceuticals, Inc.
The collaboration with VA Greater Los Angeles Healthcare System is nation's first to validate deep learning algorithms in medical imaging of veterans with prostate cancer
Final Voting Results Confirm that Approximately Two-Thirds of the Votes Cast Were Against the Re-Election of Peter Crowley and Michael Kishbauch
I'm looking forward to hearing from Progenics Pharmaceuticals and Builders FirstSource.
Commences Search Process to Identify New Board Candidates, Welcomes Input from All Shareholders
Agrees with ISS that "Board Level Change is Warranted, With the Ultimate Goal of Enhancing Shareholder Board Oversight"
-Commercial Leader Brings Deep Experience in Radiopharmaceuticals and Oncology-
Agrees with ISS that the Board's Focus Should Be on Why Shareholder Returns Have Been Weak and Why Progenics has "Experienced Recent, Significant Delays in Both Drug Development and Commercialization"
ISS Believes Velan Presented a "Compelling Argument that Board Level Change is Warranted" to Enhance "Shareholder Board Oversight"
Highlights how the Board Continues to Distort the Truth and Mislead Stockholders in an Attempt to Preserve the Troubling Status Quo and Avoid Accountability at All Costs
Investors in Progenics Pharmaceuticals, Inc. saw new options begin trading this week, for the February 2020 expiration.
Highlights How the Board is Distorting the Truth, Mischaracterizing the Company's Current Dire State and Misleading Stockholders in an Attempt to Preserve the Troubling Status Quo
Details the Persistent Performance, Execution, Governance and Transparency Shortcomings that Have Led to the Destruction of Significant Value
In trading on Thursday, shares of Progenics Pharmaceuticals, Inc. crossed above their 200 day moving average of $4.99, changing hands as high as $5.07 per share.
Actual Stockholders, the True Owners of the Company, Deserve Answers and Clarity
Highlights the Multiple Ways Peter Crowley and Michael Kishbauch have Failed Stockholders While the Board Disingenuously Touts its "Significant Progress" and Self-Proclaimed Mastery
Oops, They Did it Again - Last Week the Board Chose to Further Dilute Stockholders, Proving Toxic Misalignment of Interests
Clarifies that the Board is Not a "Fellow Shareholder" and Expresses Concern with the Misalignment of Interests with Progenics Stockholders
Sends Letter to Fellow Stockholders Detailing the Persistent Performance, Execution, Accountability, Governance and Transparency Shortcomings that Have Led to the Destruction of Significant Value
Investors in Progenics Pharmaceuticals, Inc. saw new options begin trading this week, for the July 19th expiration.
Believes Progenics Board and Senior Management Continue to Fail at Explaining Poor Performance and Instead, Hide Behind Insufficient Disclosure
Filed Preliminary Proxy Materials Seeking Stockholder Support Against the Election of Peter J. Crowley and Michael D. Kishbauch at the Company's 2019 Annual Meeting to Send a Clear Message that Meaningful Change is Required
Sign up to get started or log in to see your watchlist.
Enter a symbol above to add it to your watchlist.
A confirmation email has been sent to the address provided during registration. Please click on the appropriate link to confirm your email address.